The Food and Drug Administration late last night announced amendments of Pfizer and Moderna’s COVID-19 vaccine emergency use authorizations to allow for the use of a third, additional dose for certain immunocompromised individuals. FDA specifically mentioned boosters for solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. The agency instructs that the third dose be administered at least 28 days following the two-dose regimen of the same vaccine to individuals ages 18 or older for Moderna and ages 12 or older for Pfizer. The Centers for Disease Control and Prevention’s vaccine advisory committee today voted unanimously to recommend a third dose of the Pfizer and Moderna Covid-19 vaccines for those immunocompromised patients, pending final approval from CDC Director Rochelle Walensky, M.D.

Following FDA’s announcement, the Centers for Medicare & Medicaid Services confirmed  that such boosters are to be made available at no cost to immunocompromised Medicare beneficiaries. CMS says that the Medicare program will continue to pay providers $40 to administer this additional dose, the same amount it pays for other doses of the COVID-19 vaccine.
 

Related News Articles

Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…